Craigie’s Coda At Church & Dwight: Vitamin Production Capacity Boost

Production on additional lines starts and the boost in supplies of L'il Critters children’s and Vitafusion adult vitamins comes not a moment too soon. “We have been living hand to mouth for a number og months as demand has exceeded our capacity,” says CEO James Craigie, who is retiring.

CEO James Craigie will leave Church & Dwight Co. Inc. with the firm better prepared to meet demand for its primary consumer health sales drivers, L'il Critters and Vitafusion gummy vitamins.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Postmarketing Surprise Is Latest Plot Twist For Novavax’s COVID-19 Vaccine BLA

 

Three weeks after its user fee goal date, the FDA demanded a postmarketing commitment “to generate additional data,” Novavax said.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By 

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Gene Therapy Sponsor INTERACT, Pre-IND Meeting Confusion Lingers Despite FDA Guidance

 
• By 

PhRMA questioned whether proof-of-concept studies are needed before an INTERACT meeting and said a draft guidance describing the timing of definitive toxicology studies creates confusion.

Europe Should Pay Drug Prices More In Line With US, Two Pharma CEOs Argue

 
• By 

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

More from North America

Proposed HHS Budget Would Eliminate Medicare Negotiation Program Start-Up Funding

 
• By 

The preliminary budget document supports legislation clawing back funds appropriated for the program.

FDA Leadership Shuffle Continues: Lowell Zeta Returns As OPDP, OGD Leaders Depart

 

Lowell Zeta, a senior counselor at the FDA from 2020 to 2021, returns as deputy commissioner for strategic initiatives. The agency also names a new acting CIO and acting CVM director, but OGD's Ted Sherwood and OPDP's Catherine Gray retired.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.